Published in J Natl Cancer Inst on January 04, 2013
PD-1 Inhibitors Consolidation in Extensive-stage Small Cell Lung Cancer (PICARES) | NCT03971214
Immune Checkpoint Blockade in Cancer Therapy. J Clin Oncol (2015) 4.25
An abscopal response to radiation and ipilimumab in a patient with metastatic non-small cell lung cancer. Cancer Immunol Res (2013) 2.30
Stereotactic Radiation Therapy Augments Antigen-Specific PD-1-Mediated Antitumor Immune Responses via Cross-Presentation of Tumor Antigen. Cancer Immunol Res (2014) 2.00
CDKN1A regulates Langerhans cell survival and promotes Treg cell generation upon exposure to ionizing irradiation. Nat Immunol (2015) 1.73
Charged particle therapy--optimization, challenges and future directions. Nat Rev Clin Oncol (2013) 1.70
Combination cancer immunotherapies tailored to the tumour microenvironment. Nat Rev Clin Oncol (2015) 1.54
Combining radiation and immunotherapy: a new systemic therapy for solid tumors? Cancer Immunol Res (2014) 1.43
Radiation fosters dose-dependent and chemotherapy-induced immunogenic cell death. Oncoimmunology (2014) 1.35
Trial Watch: Anticancer radioimmunotherapy. Oncoimmunology (2013) 1.31
Tumour-infiltrating lymphocytes predict response to definitive chemoradiotherapy in head and neck cancer. Br J Cancer (2013) 1.30
Nivolumab in NSCLC: latest evidence and clinical potential. Ther Adv Med Oncol (2015) 1.21
Ablative Tumor Radiation Can Change the Tumor Immune Cell Microenvironment to Induce Durable Complete Remissions. Clin Cancer Res (2015) 1.15
Current status and perspectives in translational biomarker research for PD-1/PD-L1 immune checkpoint blockade therapy. J Hematol Oncol (2016) 1.12
NK Cell-Mediated Antibody-Dependent Cellular Cytotoxicity in Cancer Immunotherapy. Front Immunol (2015) 1.11
Ionizing radiation, ion transports, and radioresistance of cancer cells. Front Physiol (2013) 1.09
New challenges in high-energy particle radiobiology. Br J Radiol (2014) 1.08
The biology and treatment of oligometastatic cancer. Oncotarget (2015) 1.08
Radical irradiation of extracranial oligometastases. J Clin Oncol (2014) 1.07
Interaction of radiation therapy with molecular targeted agents. J Clin Oncol (2014) 1.05
TH2-Polarized CD4(+) T Cells and Macrophages Limit Efficacy of Radiotherapy. Cancer Immunol Res (2015) 1.03
Combinations of radiation therapy and immunotherapy for melanoma: a review of clinical outcomes. Int J Radiat Oncol Biol Phys (2014) 1.03
Physical modalities inducing immunogenic tumor cell death for cancer immunotherapy. Oncoimmunology (2015) 1.02
Combinations of immunotherapy and radiation in cancer therapy. Front Oncol (2014) 1.01
TGFβ Is a Master Regulator of Radiation Therapy-Induced Antitumor Immunity. Cancer Res (2015) 0.98
Cancer immunotherapy in clinical practice -- the past, present, and future. Chin J Cancer (2014) 0.98
A systematic evaluation of abscopal responses following radiotherapy in patients with metastatic melanoma treated with ipilimumab. Oncoimmunology (2015) 0.96
Molecular radiobiology: the state of the art. J Clin Oncol (2014) 0.96
Defining molecular signature of pro-immunogenic radiotherapy targets in human prostate cancer cells. Radiat Res (2014) 0.95
Radiotherapy combined with TLR7/8 activation induces strong immune responses against gastrointestinal tumors. Oncotarget (2015) 0.94
Is tumor (R)ejection by the immune system the "5th R" of radiobiology? Oncoimmunology (2014) 0.94
Tumor radiation therapy creates therapeutic vaccine responses to the colorectal cancer antigen GUCY2C. Int J Radiat Oncol Biol Phys (2014) 0.93
Targeting the inhibitory receptor CTLA-4 on T cells increased abscopal effects in murine mesothelioma model. Oncotarget (2015) 0.93
Radiation-induced survival responses promote immunogenic modulation to enhance immunotherapy in combinatorial regimens. Oncoimmunology (2014) 0.92
Antitumor immunity induced after α irradiation. Neoplasia (2014) 0.91
Molecular markers to predict clinical outcome and radiation induced toxicity in lung cancer. J Thorac Dis (2014) 0.91
Immunotherapy for prostate cancer: recent developments and future challenges. Cancer Metastasis Rev (2014) 0.90
Stereotactic body radiotherapy (sbrt) in lung oligometastatic patients: role of local treatments. Radiat Oncol (2014) 0.90
The potential and hurdles of targeted alpha therapy - clinical trials and beyond. Front Oncol (2014) 0.90
Radiation therapy generates platelet-activating factor agonists. Oncotarget (2016) 0.89
Emerging Opportunities and Challenges in Cancer Immunotherapy. Clin Cancer Res (2016) 0.89
Portrait of inflammatory response to ionizing radiation treatment. J Inflamm (Lond) (2015) 0.89
Molecularly targeted agents as radiosensitizers in cancer therapy--focus on prostate cancer. Int J Mol Sci (2013) 0.89
Expanding the use of monoclonal antibody therapy of cancer by using ionising radiation to upregulate antibody targets. Br J Cancer (2014) 0.89
Nivolumab, anti-programmed death-1 (PD-1) monoclonal antibody immunotherapy: Role in advanced cancers. Hum Vaccin Immunother (2016) 0.89
Ipilmumab and cranial radiation in metastatic melanoma patients: a case series and review. J Immunother Cancer (2015) 0.88
Impact of the immune system and immunotherapy in colorectal cancer. J Gastrointest Oncol (2015) 0.87
Whole Tumor Antigen Vaccines: Where Are We? Vaccines (Basel) (2015) 0.87
Myeloid cell signatures in tumor microenvironment predicts therapeutic response in cancer. Onco Targets Ther (2016) 0.86
The optimal partnership of radiation and immunotherapy: from preclinical studies to clinical translation. Radiat Res (2014) 0.86
Therapeutic Implications for Overcoming Radiation Resistance in Cancer Therapy. Int J Mol Sci (2015) 0.86
Stereotactic radiation therapy combined with immunotherapy: augmenting the role of radiation in local and systemic treatment. Oncology (Williston Park) (2015) 0.85
Differential expression of stress and immune response pathway transcripts and miRNAs in normal human endothelial cells subjected to fractionated or single-dose radiation. Mol Cancer Res (2014) 0.85
Strategies for combining immunotherapy with radiation for anticancer therapy. Immunotherapy (2015) 0.84
Immunotherapy for human papillomavirus-associated disease and cervical cancer: review of clinical and translational research. J Gynecol Oncol (2016) 0.83
Phase Ib study evaluating a self-adjuvanted mRNA cancer vaccine (RNActive®) combined with local radiation as consolidation and maintenance treatment for patients with stage IV non-small cell lung cancer. BMC Cancer (2014) 0.83
The potential of radiotherapy to enhance the efficacy of renal cell carcinoma therapy. Oncoimmunology (2015) 0.83
The TLR7 agonist imiquimod as an adjuvant for radiotherapy-elicited in situ vaccination against breast cancer. Oncoimmunology (2013) 0.83
Immunotherapy for solid tumors--a review for surgeons. J Surg Res (2013) 0.83
Quantitative histology analysis of the ovarian tumour microenvironment. Sci Rep (2015) 0.83
NHS-IL2 combined with radiotherapy: preclinical rationale and phase Ib trial results in metastatic non-small cell lung cancer following first-line chemotherapy. J Transl Med (2015) 0.83
The Concept of Hormesis in Cancer Therapy - Is Less More? Cureus (2015) 0.82
Immunotherapy in lung cancer. Transl Lung Cancer Res (2014) 0.82
Radiation therapy and the abscopal effect: a concept comes of age. Ann Transl Med (2016) 0.82
Immunodynamics: a cancer immunotherapy trials network review of immune monitoring in immuno-oncology clinical trials. J Immunother Cancer (2016) 0.81
Dissecting the molecular mechanism of ionizing radiation-induced tissue damage in the feather follicle. PLoS One (2014) 0.81
The Evolving Role of Immune Checkpoint Inhibitors in Cancer Treatment. Oncologist (2015) 0.81
An ecological measure of immune-cancer colocalization as a prognostic factor for breast cancer. Breast Cancer Res (2015) 0.81
Considerations for combined immune checkpoint modulation and radiation treatment. Radiat Res (2014) 0.81
PD-L1 blockade enhances response of pancreatic ductal adenocarcinoma to radiotherapy. EMBO Mol Med (2016) 0.81
Peripheral myeloid-derived suppressor and T regulatory PD-1 positive cells predict response to neoadjuvant short-course radiotherapy in rectal cancer patients. Oncotarget (2015) 0.81
Trial Watch: Immunotherapy plus radiation therapy for oncological indications. Oncoimmunology (2016) 0.81
Advances in targeted and immunobased therapies for colorectal cancer in the genomic era. Onco Targets Ther (2016) 0.81
Enhancing the efficacy of radiation therapy: premises, promises, and practicality. J Clin Oncol (2014) 0.81
Current clinical trials testing the combination of immunotherapy with radiotherapy. J Immunother Cancer (2016) 0.81
The role of PD-L1 in the radiation response and clinical outcome for bladder cancer. Sci Rep (2016) 0.81
Radiotherapy: Changing the Game in Immunotherapy. Trends Cancer (2016) 0.80
Combination regimens of radiation therapy and therapeutic cancer vaccines: mechanisms and opportunities. Semin Radiat Oncol (2015) 0.80
Tumor infiltrating lymphocytes (TILs) before and after neoadjuvant chemoradiotherapy and its clinical utility for rectal cancer. Am J Cancer Res (2015) 0.80
Programmed cell death-1 blockade in recurrent disseminated Ewing sarcoma. J Hematol Oncol (2016) 0.80
Checkpoint Inhibitors and Their Application in Breast Cancer. Breast Care (Basel) (2016) 0.80
Mechanistic Insights into Molecular Targeting and Combined Modality Therapy for Aggressive, Localized Prostate Cancer. Front Oncol (2016) 0.79
Enhancing radiotherapy for lung cancer using immunoadjuvants delivered in situ from new design radiotherapy biomaterials: a preclinical study. Phys Med Biol (2016) 0.79
The Rationale for Targeted Therapies and Stereotactic Radiosurgery in the Treatment of Brain Metastases. Oncologist (2016) 0.79
Emerging Treatment Paradigms in Radiation Oncology. Clin Cancer Res (2015) 0.79
Distinct patterns of infiltrating CD8+ T cells in HPV+ and CD68 macrophages in HPV- oropharyngeal squamous cell carcinomas are associated with better clinical outcome but PD-L1 expression is not prognostic. Oncotarget (2017) 0.78
Combining Radiation Therapy with Immune Checkpoint Blockade for Central Nervous System Malignancies. Front Oncol (2016) 0.78
Fractionated Radiotherapy with 3 x 8 Gy Induces Systemic Anti-Tumour Responses and Abscopal Tumour Inhibition without Modulating the Humoral Anti-Tumour Response. PLoS One (2016) 0.78
Cancer-associated fibroblasts from lung tumors maintain their immunosuppressive abilities after high-dose irradiation. Front Oncol (2015) 0.78
Preoperative Single-Fraction Partial Breast Radiation Therapy: A Novel Phase 1, Dose-Escalation Protocol With Radiation Response Biomarkers. Int J Radiat Oncol Biol Phys (2015) 0.78
Immunotherapy for pancreatic ductal adenocarcinoma: an overview of clinical trials. Chin J Cancer Res (2015) 0.78
Control of CD8 T-Cell Infiltration into Tumors by Vasculature and Microenvironment. Adv Cancer Res (2015) 0.78
ISG15 in the tumorigenesis and treatment of cancer: An emerging role in malignancies of the digestive system. Oncotarget (2016) 0.78
Designer vaccine nanodiscs for personalized cancer immunotherapy. Nat Mater (2016) 0.78
Combination immunotherapy: a road map. J Immunother Cancer (2017) 0.77
Combination of radiotherapy and vaccination overcomes checkpoint blockade resistance. Oncotarget (2016) 0.77
L-BLP25 as a peptide vaccine therapy in non-small cell lung cancer: a review. J Thorac Dis (2014) 0.77
Personalized radiotherapy: concepts, biomarkers and trial design. Br J Radiol (2015) 0.77
Using α radiation to boost cancer immunity? Oncoimmunology (2014) 0.77
Radiotherapy as an immunological booster in patients with metastatic melanoma or renal cell carcinoma treated with high-dose Interleukin-2: evaluation of biomarkers of immunologic and therapeutic response. J Transl Med (2014) 0.77
Hallmarks of cancer: the next generation. Cell (2011) 140.01
Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med (2010) 29.75
The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer (2012) 24.94
Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials. Lancet (2005) 24.57
Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science (2006) 24.54
Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science (2011) 15.79
Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol (2002) 14.75
Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat Med (2007) 13.90
Calreticulin exposure dictates the immunogenicity of cancer cell death. Nat Med (2006) 10.54
Dendritic cells acquire antigen from apoptotic cells and induce class I-restricted CTLs. Nature (1998) 9.77
Immunologic correlates of the abscopal effect in a patient with melanoma. N Engl J Med (2012) 8.46
Interferons, immunity and cancer immunoediting. Nat Rev Immunol (2006) 8.23
The three Es of cancer immunoediting. Annu Rev Immunol (2004) 8.20
Adaptive immunity maintains occult cancer in an equilibrium state. Nature (2007) 8.14
Cancer exome analysis reveals a T-cell-dependent mechanism of cancer immunoediting. Nature (2012) 7.76
The DNA damage pathway regulates innate immune system ligands of the NKG2D receptor. Nature (2005) 7.18
Natural innate and adaptive immunity to cancer. Annu Rev Immunol (2011) 7.09
Macrophages, innate immunity and cancer: balance, tolerance, and diversity. Curr Opin Immunol (2010) 6.85
Activation of the NLRP3 inflammasome in dendritic cells induces IL-1beta-dependent adaptive immunity against tumors. Nat Med (2009) 6.73
Epitope landscape in breast and colorectal cancer. Cancer Res (2008) 5.29
Therapeutic effects of ablative radiation on local tumor require CD8+ T cells: changing strategies for cancer treatment. Blood (2009) 5.21
Cancer immunosurveillance and immunoediting: the roles of immunity in suppressing tumor development and shaping tumor immunogenicity. Adv Immunol (2006) 4.98
Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunotherapy. J Exp Med (2006) 4.84
Fractionated but not single-dose radiotherapy induces an immune-mediated abscopal effect when combined with anti-CTLA-4 antibody. Clin Cancer Res (2009) 4.58
Regulatory T cells in tumor immunity. Int J Cancer (2010) 4.53
Ionizing radiation inhibition of distant untreated tumors (abscopal effect) is immune mediated. Int J Radiat Oncol Biol Phys (2004) 4.29
Immune-mediated inhibition of metastases after treatment with local radiation and CTLA-4 blockade in a mouse model of breast cancer. Clin Cancer Res (2005) 4.23
Neoadjuvant cisplatin chemotherapy before chemoradiation: a flawed paradigm? J Clin Oncol (2007) 4.18
Immune infiltration in human tumors: a prognostic factor that should not be ignored. Oncogene (2009) 3.90
Expression of tumour-specific antigens underlies cancer immunoediting. Nature (2012) 3.89
In situ vaccination with a TLR9 agonist induces systemic lymphoma regression: a phase I/II study. J Clin Oncol (2010) 3.88
Tumor progression can occur despite the induction of very high levels of self/tumor antigen-specific CD8+ T cells in patients with melanoma. J Immunol (2005) 3.73
Combining a recombinant cancer vaccine with standard definitive radiotherapy in patients with localized prostate cancer. Clin Cancer Res (2005) 3.57
Cell death modalities: classification and pathophysiological implications. Cell Death Differ (2007) 3.19
Systemic effects of local radiotherapy. Lancet Oncol (2009) 2.97
External beam radiation of tumors alters phenotype of tumor cells to render them susceptible to vaccine-mediated T-cell killing. Cancer Res (2004) 2.91
In vivo imaging of cytotoxic T cell infiltration and elimination of a solid tumor. J Exp Med (2007) 2.89
Immune resistance orchestrated by the tumor microenvironment. Immunol Rev (2006) 2.83
Whole body irradiation; radiobiology or medicine? Br J Radiol (1953) 2.80
Radiation-induced CXCL16 release by breast cancer cells attracts effector T cells. J Immunol (2008) 2.61
The efficacy of radiotherapy relies upon induction of type i interferon-dependent innate and adaptive immunity. Cancer Res (2011) 2.60
Immature myeloid cells and cancer-associated immune suppression. Cancer Immunol Immunother (2002) 2.60
Calreticulin exposure is required for the immunogenicity of gamma-irradiation and UVC light-induced apoptosis. Cell Death Differ (2007) 2.58
Sublethal irradiation of human tumor cells modulates phenotype resulting in enhanced killing by cytotoxic T lymphocytes. Cancer Res (2004) 2.54
Two-photon imaging of intratumoral CD8+ T cell cytotoxic activity during adoptive T cell therapy in mice. J Clin Invest (2008) 2.52
Irradiation of tumor cells up-regulates Fas and enhances CTL lytic activity and CTL adoptive immunotherapy. J Immunol (2003) 2.51
B7-H1 pathway and its role in the evasion of tumor immunity. J Mol Med (Berl) (2003) 2.48
Perforin and interferon-gamma activities independently control tumor initiation, growth, and metastasis. Blood (2001) 2.45
Twelve immunotherapy drugs that could cure cancers. Immunol Rev (2008) 2.45
Transforming growth factor-beta and the immune response: implications for anticancer therapy. Clin Cancer Res (2007) 2.44
Dendritic cells as adjuvants for immune-mediated resistance to tumors. J Exp Med (1997) 2.33
Combining radiotherapy and immunotherapy: a revived partnership. Int J Radiat Oncol Biol Phys (2005) 2.29
Abscopal regression of hepatocellular carcinoma after radiotherapy for bone metastasis. Gut (1998) 2.11
Cell intrinsic mechanisms of T-cell inhibition and application to cancer therapy. Immunol Rev (2008) 2.08
Increased tumor necrosis factor alpha mRNA after cellular exposure to ionizing radiation. Proc Natl Acad Sci U S A (1989) 2.05
A sense of danger from radiation. Radiat Res (2004) 2.02
The co-translocation of ERp57 and calreticulin determines the immunogenicity of cell death. Cell Death Differ (2008) 2.01
Tumor-infiltrating myeloid cells induce tumor cell resistance to cytotoxic T cells in mice. J Clin Invest (2011) 2.01
Transforming growth factor-beta activation in irradiated murine mammary gland. J Clin Invest (1994) 2.01
Targeting toll-like receptor 9 with CpG oligodeoxynucleotides enhances tumor response to fractionated radiotherapy. Clin Cancer Res (2005) 1.97
Chemotherapy and radiotherapy: cryptic anticancer vaccines. Semin Immunol (2010) 1.94
Radiation-induced IFN-gamma production within the tumor microenvironment influences antitumor immunity. J Immunol (2008) 1.93
Therapeutic cancer vaccines: are we there yet? Immunol Rev (2011) 1.86
Standard treatments induce antigen-specific immune responses in prostate cancer. Clin Cancer Res (2007) 1.82
Immunomodulatory effects of cyclophosphamide and implementations for vaccine design. Semin Immunopathol (2011) 1.80
Contrasting frequencies of antitumor and anti-vaccine T cells in metastases of a melanoma patient vaccinated with a MAGE tumor antigen. J Exp Med (2005) 1.75
Restoration of the immunogenicity of cisplatin-induced cancer cell death by endoplasmic reticulum stress. Oncogene (2010) 1.75
Regression of non-irradiated metastases after extracranial stereotactic radiotherapy in metastatic renal cell carcinoma. Acta Oncol (2006) 1.74
Impaired interferon signaling is a common immune defect in human cancer. Proc Natl Acad Sci U S A (2009) 1.66
Combination of conformal radiotherapy and intratumoral injection of adoptive dendritic cell immunotherapy in refractory hepatoma. J Immunother (2005) 1.65
Cardiac glycosides exert anticancer effects by inducing immunogenic cell death. Sci Transl Med (2012) 1.63
T-cell responses to survivin in cancer patients undergoing radiation therapy. Clin Cancer Res (2008) 1.61
Flt3-ligand administration after radiation therapy prolongs survival in a murine model of metastatic lung cancer. Cancer Res (1999) 1.60
Maximizing tumor immunity with fractionated radiation. Int J Radiat Oncol Biol Phys (2011) 1.60
Radiotherapy increases the permissiveness of established mammary tumors to rejection by immunomodulatory antibodies. Cancer Res (2012) 1.59
Suppressing T cell motility induced by anti-CTLA-4 monotherapy improves antitumor effects. J Clin Invest (2012) 1.55
The combination of ionizing radiation and peripheral vaccination produces long-term survival of mice bearing established invasive GL261 gliomas. Clin Cancer Res (2006) 1.51
Sensors of ionizing radiation effects on the immunological microenvironment of cancer. Int J Radiat Biol (2008) 1.49
CD8+ T cell concentration determines their efficiency in killing cognate antigen-expressing syngeneic mammalian cells in vitro and in mouse tissues. J Exp Med (2010) 1.48
Effect of host immune capability on radiocurability and subsequent transplantability of a murine fibrosarcoma. J Natl Cancer Inst (1979) 1.48
Isoform-specific activation of latent transforming growth factor beta (LTGF-beta) by reactive oxygen species. Radiat Res (2006) 1.47
The tipping point for combination therapy: cancer vaccines with radiation, chemotherapy, or targeted small molecule inhibitors. Semin Oncol (2012) 1.44
Radiation enhances regulatory T cell representation. Int J Radiat Oncol Biol Phys (2010) 1.39
Combination chemotherapy and radiation of human squamous cell carcinoma of the head and neck augments CTL-mediated lysis. Clin Cancer Res (2006) 1.36
Radiotherapy potentiates the therapeutic efficacy of intratumoral dendritic cell administration. Cancer Res (2003) 1.35
TGFβ1 inhibition increases the radiosensitivity of breast cancer cells in vitro and promotes tumor control by radiation in vivo. Clin Cancer Res (2011) 1.30
Enhancement of antitumor radiation efficacy and consistent induction of the abscopal effect in mice by ECI301, an active variant of macrophage inflammatory protein-1alpha. Clin Cancer Res (2008) 1.29
Macrophages from irradiated tumors express higher levels of iNOS, arginase-I and COX-2, and promote tumor growth. Int J Radiat Oncol Biol Phys (2007) 1.28
CpG oligodeoxynucleotide enhances tumor response to radiation. Cancer Res (2004) 1.25
Rapid induction of cytokine gene expression in the lung after single and fractionated doses of radiation. Int J Radiat Biol (1999) 1.24
Abscopal effect of radiation in papillary adenocarcinoma. Br J Radiol (1973) 1.24
The convergence of radiation and immunogenic cell death signaling pathways. Front Oncol (2012) 1.24
Late and persistent up-regulation of intercellular adhesion molecule-1 (ICAM-1) expression by ionizing radiation in human endothelial cells in vitro. Int J Radiat Biol (1997) 1.20
Immune suppression in the tumor microenvironment: a role for dendritic cell-mediated tolerization of T cells. Cancer Immunol Immunother (2012) 1.19
Combination of gamma-irradiation and dendritic cell administration induces a potent antitumor response in tumor-bearing mice: approach to treatment of advanced stage cancer. Int J Cancer (2001) 1.19
Local control by radiotherapy: is that all there is? Breast Cancer Res (2008) 1.18
Combination of external beam radiotherapy (EBRT) with intratumoral injection of dendritic cells as neo-adjuvant treatment of high-risk soft tissue sarcoma patients. Int J Radiat Oncol Biol Phys (2011) 1.17
Abscopal regression of antigen disparate tumors by antigen cascade after systemic tumor vaccination in combination with local tumor radiation. Cancer Biother Radiopharm (2012) 1.16
TBI during BM and SCT: review of the past, discussion of the present and consideration of future directions. Bone Marrow Transplant (2010) 1.15
Prognostic value of tumor-infiltrating lymphocytes in triple-negative breast cancers from two phase III randomized adjuvant breast cancer trials: ECOG 2197 and ECOG 1199. J Clin Oncol (2014) 5.61
Fractionated but not single-dose radiotherapy induces an immune-mediated abscopal effect when combined with anti-CTLA-4 antibody. Clin Cancer Res (2009) 4.58
Systemic effects of local radiotherapy. Lancet Oncol (2009) 2.97
Radiation-induced CXCL16 release by breast cancer cells attracts effector T cells. J Immunol (2008) 2.61
Suppressing T cell motility induced by anti-CTLA-4 monotherapy improves antitumor effects. J Clin Invest (2012) 1.55
The combination of ionizing radiation and peripheral vaccination produces long-term survival of mice bearing established invasive GL261 gliomas. Clin Cancer Res (2006) 1.51
Topical TLR7 agonist imiquimod can induce immune-mediated rejection of skin metastases in patients with breast cancer. Clin Cancer Res (2012) 1.46
Synergy of topical toll-like receptor 7 agonist with radiation and low-dose cyclophosphamide in a mouse model of cutaneous breast cancer. Clin Cancer Res (2012) 1.31
Invariant natural killer T cells regulate breast cancer response to radiation and CTLA-4 blockade. Clin Cancer Res (2009) 1.31
TGFβ1 inhibition increases the radiosensitivity of breast cancer cells in vitro and promotes tumor control by radiation in vivo. Clin Cancer Res (2011) 1.30
The convergence of radiation and immunogenic cell death signaling pathways. Front Oncol (2012) 1.24
Downregulation of major histocompatibility complex antigens in invading glioma cells: stealth invasion of the brain. Lab Invest (2005) 1.22
Radiation therapy to convert the tumor into an in situ vaccine. Int J Radiat Oncol Biol Phys (2012) 1.19
Local control by radiotherapy: is that all there is? Breast Cancer Res (2008) 1.18
Expression of cancer testis antigens in human BRCA-associated breast cancers: potential targets for immunoprevention? Cancer Immunol Immunother (2011) 1.08
Up-regulation of the pro-inflammatory chemokine CXCL16 is a common response of tumor cells to ionizing radiation. Radiat Res (2010) 1.06
Effects of chemoradiation on tumor-host interactions: the immunologic side. J Clin Oncol (2008) 1.00
HLA-A2-restricted CD8+-cytotoxic-T-cell responses to novel epitopes in Mycobacterium tuberculosis superoxide dismutase, alanine dehydrogenase, and glutamine synthetase. Infect Immun (2004) 0.93
Radiotherapy enhances antitumor effect of anti-CD137 therapy in a mouse Glioma model. Radiat Res (2010) 0.91
Invariant NKT cells as novel targets for immunotherapy in solid tumors. Clin Dev Immunol (2012) 0.86
The numbers of FoxP3+ lymphocytes in sentinel lymph nodes of breast cancer patients correlate with primary tumor size but not nodal status. Cancer Invest (2011) 0.79
Exercise in Regulation of Inflammation-Immune Axis Function in Cancer Initiation and Progression. Oncology (Williston Park) (2015) 0.77
Role of the crosstalk between CTLA-4 and NKG2D in the development of anti-CTLA-4 treatment strategies. Immunotherapy (2013) 0.76
Research highlights: Immunotherapy. Immunotherapy (2009) 0.75